Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Innovent Biologics ( (HK:1801) ).
Innovent Biologics has announced the appointment of Dr. Stephen A. Sherwin as an independent non-executive director and a member of the strategy committee, effective August 26, 2025. Dr. Sherwin brings extensive experience in the life sciences and oncology sectors, which is expected to enhance Innovent’s strategic direction and strengthen its position in the biotechnology industry.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$109.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a company incorporated in the Cayman Islands, primarily operating in the biotechnology industry. The company focuses on developing and manufacturing biologic drugs, particularly in the field of oncology, aiming to provide innovative solutions for cancer treatment.
Average Trading Volume: 23,906,438
Technical Sentiment Signal: Buy
Current Market Cap: HK$171.2B
Learn more about 1801 stock on TipRanks’ Stock Analysis page.